title: SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties.
abstract: We found a potent and selective sigma 1 (sigma 1) receptor ligand, SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride). This compound had a high affinity for sigma 1 receptor subtype (IC50 = 17 +/- 1.9 nM), but a low affinity for sigma 2 receptor subtype (IC50 = 1800 +/- 310 nM). The present study examines the effect of this compound on the central cholinergic functions, since sigma receptor has been reported to interact with the central cholinergic neurons. SA4503 elicited the increase in extracellular acetylcholine level in rat frontal cortex, while it did not affect the striatal acetylcholine level. On the other hand, tetrahydroaminoacridine (THA), an acetylcholinesterase (AChE) inhibitor, increased the extracellular acetylcholine level in both regions. Although both compounds had anti-amnesic effect against scopolamine-induced memory impairment, THA also induced catalepsy in rats. These results suggest that SA4503 may be a novel cognitive enhancer, with sigma 1 receptor agonistic properties. In addition, SA4503 does not cause striatal cholinomimetic side-effects, which is different from THA.
authors.affiliation: Central Research Laboratorie, Santen Pharmaceutical Co., Ltd., Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Matsuno
authors.forename: T
authors.initials: T
authors.lastname: Senda
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Okamoto
authors.forename: K
authors.initials: K
authors.lastname: Nakata
authors.forename: S
authors.initials: S
authors.lastname: Mita
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000609:Aminoacridines / Q000494:pharmacology; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced / Q000523:psychology; D018680:Cholinergic Antagonists / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D003071:Cognition / Q000187:drug effects*; D018492:Dopamine Antagonists / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D066298:In Vitro Techniques; D017551:Microdialysis; D018697:Nootropic Agents / Q000378:metabolism / Q000494:pharmacology*; D010275:Parasympathetic Nervous System / Q000187:drug effects*; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D017480:Receptors, sigma / Q000819:agonists* / Q000378:metabolism; D012601:Scopolamine / Q000494:pharmacology
chemical_list: D000609:Aminoacridines; D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D018492:Dopamine Antagonists; D018697:Nootropic Agents; D010879:Piperazines; D017480:Receptors, sigma; C101789:SA 4503; D012601:Scopolamine; D006220:Haloperidol; D000109:Acetylcholine